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This viewpoint briefly reviews the impact of Locked Nucleic 5 
Acid (LNA) oligonucleotides, first described in a ChemComm 
paper in 1998.  A number of unique applications in 
oligonucleotide biotechnology have been made possible by the 
high binding affinity and specificity of LNA, and these 
provide the main focus of the viewpoint. 10 
I recently read a fascinating analysis of the role of the internet in 
the uprisings in Egypt, Tunisia and elsewhere over the past 
several years.  Did social media really change anything 
fundamental that allowed these uprisings, or did they simply 
make communication faster?  Zeynep Tufecki’s response is that 15 
faster is different: the speed of person-to-person communication 
afforded by the internet allowed coordination of protests and 
circulation of ideas in ways that simply wouldn’t have been 
possible at all with older types of communication (e.g. state-
controlled mass media or one-on-one conversations).1 20 
 A parallel question could be posed about the effect of locked 
nucleic acid (LNA, Figure 1) on oligonucleotide chemical 
biology.  Has it really changed the field, or does it simply bind 
with higher affinity than its predecessors?  And I would contend 
that the answer is again parallel:  tighter binding is different.  In 25 
this viewpoint I will examine several developments in 
oligonucleotide biotechnology that were made possible by LNA’s 
very high binding affinity and specificity. 
 Foundational papers on LNA were independently published by 
both the Wengel2, 3 and Imanishi5 groups.  Wengel’s ChemComm 30 
paper,2 the subject of this viewpoint, was the first publication of 
LNA oligonucleotides and their dramatically increased binding 
affinity.  For mixed sequences, inserting several locked 
nucleotides into a DNA oligomer gave a stabilization of about 
5 °C per locked nucleotide when binding to DNA and 7-8 °C 35 
when binding to RNA.2  Moreover, the binding showed high 
specificity in that a single mismatched base opposite LNA led to 
a more pronounced drop in denaturation temperature than a 
mismatch opposite DNA.9  
 Nucleic acid duplex formation is generally driven by enthalpy, 40 
and disfavoured by entropy. Before the development of LNA, 
there was already an awareness that preorganization might be 
able to reduce the entropic penalty of duplex formation.10 And if 
the preorganized conformation was appropriate for binding, the 
enthalpic term would be maintained, thus increasing the overall 45 
binding affinity.  Other ways to increase the strength of duplex 
binding, including addition of positive charge and conjugation of 
intercalators or minor-groove binders, can decrease the specificity 
of binding, while preorganization showed the potential to 
increase both affinity and specificity.10  50 
 Thus a number of groups had been working on constrained 
nucleotides for several years before LNA was published.  None 
of the previous constrained analogues, however, showed the 
degree of increase in binding affinity conferred by LNA.  It is 
interesting that LNA, the most successful of the constrained 55 
nucleic acids, is also arguably the simplest conceivable structure, 
bearing only a single extra atom relative to RNA (Figure 1).   
 The oligonucleotide community, therefore, warmly welcomed 
the arrival of LNA. The compatibility of LNA synthesis with 
normal phosphoramidite coupling chemistry allowed it to be 60 
applied very readily to the full range of challenges facing the 
field.  
 LNA was very quickly applied to the field of gene silencing11 
by antisense oligonucleotides (ASOs, Figure 2). LNA-modified 
ASOs often show increased potency relative to other chemically 65 
modified ASOs.12, 13 Five LNA oligonucleotides are in clinical 
trials.14  
 More recently, the high binding affinity of LNA was applied to 
allow the development of much shorter ASOs than previously 
thought possible.4, 15 Sequences as short as 12-mers, containing 70 
LNA wings surrounding an 8-mer DNA window, were active in 
huh-7 cells and in vivo in mice and monkeys.4  Longer 
oligonucleotides up to 15 or 16-mers showed similar potencies in 
cell culture (IC50 values of ~0.5 nM) but lower efficacies in vivo.  
Some subsequent studies have found that 16-mers may be 75 
preferable to 12-mers for certain applications,16 but even 16 nt is 
shorter than would have previously been considered for most 
antisense chemistries.  Short LNA-modified ASOs are also ideal 
for delivery to cultured cells in the absence of lipid, termed 
gymnotic delivery.17   80 
 Certain LNAs have significant toxicity,13 but it is generally 
possible to find sequences with an acceptable toxicity profile.  
Nevertheless, an antisense oligonucleotide targeting PCSK9 was 
recently pulled from clinical trials after acute kidney injury was 
Figure 1.  A comparison of the structures of DNA, RNA and LNA.  
LNA is shown both from the normal perspective of drawing nucleotides 
and the normal perspective of drawing [2.2.1] bicyclic structures. 
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observed in one patient in a Phase I trial.18  It is not clear how 
much of this toxicity was due to unintended but on-target gene 
silencing in the kidney, and how much to sequence-dependent 
off-target effects. Nor is it clear how much toxicity was due to 
LNA, and how much to other aspects of the oligonucleotide 5 
chemistry (see below for a discussion of backbone toxicity). 
Nevertheless, this failed trial is a setback for LNA and for the 
antisense approach. 
 Another gene-silencing approach, RNA interference, can also 
benefit from LNA oligonucleotides.19  The RNAi technique 10 
requires double-stranded small interfering RNA (siRNA), and 
one concern is that off-target effects may arise from the so-called 
“passenger strand.”  To avoid this problem, a variant siRNA 
design was used where the passenger strand was internally 
segmented, giving two short strands rather than one long strand.8  15 
This would not have been possible without the high binding 
affinity of LNA (Figure 2).   
 High binding affinity has proven particularly important in the 
rapidly expanding field of microRNA (miRNA) research.  
miRNAs are ~20-nucleotide sequences of RNA with important 20 
biological roles.20  Because of their small size, inhibition and 
analysis of miRNAs is challenging with normal oligonucleotides.   
 Inhibition of miRNAs in cells and in vivo is a key approach to 
study miRNA function and can induce a therapeutic effect.  As 
for traditional mRNA-targeted antisense oligonucleotides, 25 
chemical modification is key to effective anti-miRNA ASO 
activity.  A 15-mer LNA mixmer oligonucleotide that targets 
miR-122 was effective in non-human primates and is currently in 
Phase II clinical trials for treatment of hepatitis C (Figure 2b).6  
 The high binding affinity of LNA allows it to go a step further 30 
than traditional miRNA inhibition, however.  Using a fully-
modified 8-mer “tiny LNA” (Figure 2c), it is possible to inhibit a 
family of miRNAs with a common seed sequence (the 6-8 
nucleotides at the 5’-end of the active miRNA).7  The seed 
sequence is key for recognition of target RNAs,20 so this 35 
approach targets a group of miRNAs that share a common 
inhibitory profile.  The tiny LNAs did not appear to be toxic or to 
downregulate mRNAs containing perfectly complementary sites.7 
 Beyond targeting various classes of RNA, another therapeutic 
gene silencing approach could involve targeting of chromosomal 40 
DNA.  LNA can be used as a triplex-forming oligonucleotide at 
dsDNA, and intriguingly it has also been used to strand-invade 
and bind DNA through Watson-Crick base pairing.21, 22 This 
property had previously only been seen for neutral-backbone 
analogues like peptide nucleic acid.  The direct binding to DNA 45 
was confirmed by a biotin-based chromatin immunoprecipitation 
experiment.21   
 LNA has had an impact in the field of diagnostics and 
bioanalysis as well.  For example, designing a DNA microarray 
to detect levels of different miRNAs from a tumour sample would 50 
be challenging because the DNA probes would have different 
melting temperatures depending on the sequence of the miRNA.  
This means that for a given annealing temperature, some of the 
DNA probes would bind more tightly to their target than others, 
making normalization very difficult.  LNA-modified arrays can 55 
be designed to have a uniform and high melting temperature for 
all probes, increasing the sensitivity of the array and giving 
consistent quantitation across the full range of miRNAs.23 
 Quantitative real-time PCR is another diagnostic approach that 
can be improved by LNA technology.  In 5'-nuclease assay PCR, 60 
a fluorescent probe oligonucleotide is degraded by the Taq 
polymerase.  This probe should have a higher binding affinity 
than the PCR primers used.  Yet in certain applications the probe 
should also be short, and must bind with high specificity, to 
detect single-nucleotide mismatches.  LNA is an ideal candidate 65 
with this range of properties and has been used to develop probes 
with higher sensitivity and specificity.24 
 The high binding affinity of LNA, of course, also comes with 
inherent challenges.  LNA oligonucleotides can form stable self-
structures (homoduplexes or hairpins), which are particularly 70 
stable if they include LNA-LNA base pairs. This is one of the 
main reasons why oligonucleotides >8 nt should generally not be 
fully modified with LNA.  Design of gapmer or mixmer 
oligonucleotides (including the placement of LNA modifications) 
must take into account the potential for stable self-structure. 75 
 As with most successes, LNA has inspired a family of 
derivatives.  These are too numerous to detail here with the 
exception of several highlights (Figure 3).  One LNA-inspired 
modification of particular note is the “constrained ethyl” or (S)-
cEt chemistry developed by ISIS and which is now, like LNA, in 80 
clinical trials (Figure 3a).  cEt modification confers high binding 
affinity like LNA, and in some cases may show reduced 
toxicity.15   Another “next-generation” bridging moiety is known 
as 2',4'-BNANC (Figure 3b), which shows increased selectivity for 
binding RNA over single-stranded DNA, and increased triplex-85 
forming ability (binding to duplex DNA).25  
 A different type of LNA-based innovation is the use of 
nitrogen rather than oxygen as the bridging heteroatom.  This 2'-
Figure 2.  Gene silencing approaches and LNA, showing designs from 
the listed references in schematic form.  (a) Gapmer ASOs contain 
high-affinity modifications on the wings and DNA in the middle, 
allowing their target to be cleaved by RNase H. Potent LNA gapmers 
can be as small as 12-13mers.4 (b) Mixmer LNAs can be used as steric 
blocking oligonucleotides – e.g. to inhibit miRNAs, inhibit translation 
or redirect splicing.6 (c) Fully modified 8-mer “tiny LNAs” can bind the 
seed sequence shared between a family of miRNAs.7  (d) small 
internally segmented interfering RNAs (sisiRNAs) contain a nick in the 
passenger strand but are taken up by the RNAi machinery.8 
 
Figure 3.  Several next-generation bridged nucleic acids.   
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amino analogue of LNA has allowed functional pendant groups 
to be projected into the minor groove of the duplex (Figure 3c).26   
 Finally it should be noted that the full family of eight LNA-
related stereoisomers has been tested and remarkably, six of them 
bind RNA with high affinity.27  Among these, α-L-LNA shows 5 
considerable promise (Figure 3d).  In contrast to LNA, which 
induces strongly A-form helices, α-L-LNA leads to a more B-
form helical structure.28  As such, it is more of a DNA mimic 
than the parent compound, but retains the rigidity of LNA (in 
contrast to DNA itself which is inherently quite flexible).   10 
    
 LNA has had a major impact across the spectrum of 
oligonucleotide biotechnology.  However, there are a number of 
challenges in using oligonucleotides that LNA has not addressed. 
The preeminent example is the challenge of delivery. 15 
Conjugation and formulation strategies are making great 
progress, but there is still a lot of work to be done, particularly for 
the question of cell-type-specific delivery.  The development of 
clinically validated strategies to target tissues outside of the liver, 
vasculature and kidneys – ideally without significant exposure to 20 
these organs – would open new doors for oligonucleotide 
therapeutics in general. 
 Secondly, for therapeutic purposes LNA is generally used in 
combination with a phosphorothioate (PS) backbone.  In this way 
it is like other antisense oligonucleotides in the clinic today.  The 25 
PS backbone provides outstanding nuclease stability and helps 
with the delivery problem.  However, PS gapmers tend to have 
high toxicity. Mipomersen, a phosphorothioate MOE gapmer 
approved by the FDA in early 2013, is associated with a risk of 
hepatotoxicity and is only available through a careful risk 30 
evaluation and mitigation program.  Thus in the areas of both 
sugar and phosphate modification, it is essential that chemists 
continue to develop creative ways to continue to improve 
potencies and toxicity profiles. 
 35 
 In this brief viewpoint I have highlighted a few areas in which 
the high binding affinity of LNA has allowed totally novel 
approaches – areas in which “tighter” has led to “different.” 
These include short antisense oligonucleotides, “tiny LNAs” for 
inhibition of miRNA families, three-stranded siRNAs, strand 40 
invasion of dsDNA at promoters, optimized miRNA arrays and 
short, specific probes for real-time PCR.  Many of these 
approaches have been demonstrated only in the past few years.  
LNA research continues to be a fruitful area and further creative 
applications will surely be explored in the years to come. 45 
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